Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application.

Dai C, Fu Y, Chen S, Li B, Yao B, Liu W, Zhu L, Chen N, Chen J, Zhang Q.

Sci China Life Sci. 2013 Jan;56(1):51-8. doi: 10.1007/s11427-012-4431-7. Epub 2013 Jan 12.

PMID:
23314867
2.

Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma.

Dai C, Fu Y, Li B, Wang Y, Zhang X, Wang J, Zhang Q.

Sci China Life Sci. 2011 Feb;54(2):128-38. doi: 10.1007/s11427-010-4124-z. Epub 2011 Feb 14.

PMID:
21318482
3.

Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent.

Tsunoda S, Ishikawa T, Yamamoto Y, Kamada H, Koizumi K, Matsui J, Tsutsumi Y, Hirano T, Mayumi T.

J Pharmacol Exp Ther. 1999 Jul;290(1):368-72.

4.

Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.

Tsutsumi Y, Kihira T, Tsunoda S, Kanamori T, Nakagawa S, Mayumi T.

Br J Cancer. 1995 May;71(5):963-8.

5.
6.

In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors.

Tsutsumi Y, Tsunoda S, Kaneda Y, Kamada H, Kihira T, Nakagawa S, Yamamoto Y, Horisawa Y, Mayumi T.

Jpn J Cancer Res. 1996 Oct;87(10):1078-85.

PMID:
8957067
7.

Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.

Yoshioka Y, Tsutsumi Y, Ikemizu S, Yamamoto Y, Shibata H, Nishibata T, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Nagata S, Yamagata Y, Mayumi T.

Biochem Biophys Res Commun. 2004 Mar 19;315(4):808-14.

PMID:
14985084
8.

Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window.

Shibata H, Yoshioka Y, Ikemizu S, Kobayashi K, Yamamoto Y, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Hayakawa T, Nagata S, Yamagata Y, Mayumi T, Kamada H, Tsutsumi Y.

Clin Cancer Res. 2004 Dec 15;10(24):8293-300.

9.

PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects.

Kim TH, Youn YS, Jiang HH, Lee S, Chen X, Lee KC.

Bioconjug Chem. 2011 Aug 17;22(8):1631-7. doi: 10.1021/bc200187k. Epub 2011 Jul 22.

PMID:
21751817
10.

Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity.

Liang L, Lin SW, Dai W, Lu JK, Yang TY, Xiang Y, Zhang Y, Li RT, Zhang Q.

J Control Release. 2012 Jun 28;160(3):618-29. doi: 10.1016/j.jconrel.2012.02.020. Epub 2012 Mar 3.

PMID:
22410114
11.

Molecular design of conjugated tumor necrosis factor-alpha: synthesis and characteristics of polyvinyl pyrrolidone modified tumor necrosis factor-alpha.

Kamada H, Tsutsumi Y, Tsunoda S, Kihira T, Kaneda Y, Yamamoto Y, Nakagawa S, Horisawa Y, Mayumi T.

Biochem Biophys Res Commun. 1999 Apr 13;257(2):448-53.

PMID:
10198233
12.

In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.

Hao YL, Deng YJ, Chen Y, Wang KZ, Hao AJ, Zhang Y.

J Pharm Pharmacol. 2005 Oct;57(10):1279-87.

PMID:
16259756
13.

Selective enhancer of tumor vascular permeability for optimization of cancer chemotherapy.

Yoshioka Y, Tsutsumi Y, Kamada H, Kihira T, Tsunoda S, Yamamoto Y, Okamoto T, Shibata H, Mukai Y, Taniai M, Shimizu T, Kawamura M, Abe Y, Nakagawa S, Mayumi T.

Biol Pharm Bull. 2004 Mar;27(3):437-9.

14.
15.

Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice.

Kamada H, Tsutsumi Y, Yamamoto Y, Kihira T, Kaneda Y, Mu Y, Kodaira H, Tsunoda SI, Nakagawa S, Mayumi T.

Cancer Res. 2000 Nov 15;60(22):6416-20.

16.
17.

Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation.

Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ 3rd, Kraft SL, Gustafson DL, Vail DM.

Clin Cancer Res. 2010 Mar 1;16(5):1498-508. doi: 10.1158/1078-0432.CCR-09-2804. Epub 2010 Feb 16.

18.

Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its anti-tumor potency.

Tsutsumi Y, Kihira T, Yamamoto S, Kubo K, Nakagawa S, Miyake M, Horisawa Y, Kanamori T, Ikegami H, Mayumi T.

Jpn J Cancer Res. 1994 Jan;85(1):9-12.

PMID:
8106293
19.

PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency.

Li YP, Pei YY, Ding J, Shen ZM, Zhang XY, Gu ZH, Zhou JJ.

Acta Pharmacol Sin. 2001 Jun;22(6):549-55.

20.

Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.

Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J, Zalipsky S.

Clin Cancer Res. 2006 Mar 15;12(6):1913-20.

Supplemental Content

Support Center